Patents by Inventor Philip Thorne

Philip Thorne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Adamantane derivatives
    Publication number: 20090176853
    Abstract: The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CH2 or CH2CH2, E represents C(O)NH or NHC(O) and R3 represents a group of formula (I).
    Type: Application
    Filed: December 4, 2008
    Publication date: July 9, 2009
    Inventors: Lilian Alcaraz, Moya Caffrey, Mark Furber, Timothy Luker, Michael Mortimore, Austen Pimm, Philip Thorne, Paul Willis
  • Adamantane derivatives
    Publication number: 20080139636
    Abstract: The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CH2 or CH2CH2, E represents C(O)NH or NHC(O) and R3 represents a group of formula (I).
    Type: Application
    Filed: June 20, 2007
    Publication date: June 12, 2008
    Inventors: Lilian Alcaraz, Moya Caffrey, Mark Furber, Timothy Luker, Michael Mortimore, Austen Pimm, Philip Thorne, Paul Willis
  • Adamantane derivatives
    Patent number: 7297818
    Abstract: The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: November 20, 2007
    Assignee: AstraZeneca AB
    Inventor: Philip Thorne
  • Adamantane derivatives
    Publication number: 20070082957
    Abstract: The invention provides adamantane derivatives of formula (I), a process for the their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CH2 or CH2CH2, E represents C(O)NH or NHC(O) and R3 represents a group of formula (I).
    Type: Application
    Filed: September 29, 2006
    Publication date: April 12, 2007
    Inventors: Lilian Alcaraz, Moya Caffrey, Mark Furber, Timothy Luker, Michael Mortimore, Austen Pimm, Philip Thorne, Paul Willis
  • Adamantane derivatives
    Patent number: 7132457
    Abstract: The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CH2 or CH2CH2, E represents C(O)NH or NHC(O) and R3 represents a group of formula (I).
    Type: Grant
    Filed: March 31, 2004
    Date of Patent: November 7, 2006
    Assignee: AstraZeneca AB
    Inventors: Lilian Alcaraz, Mark Furber, Michael Mortimore, Austen Pimm, Philip Thorne, Paul Willis
  • Treatment of skin disorders using thieno[2,3-D]pyrimidinediones
    Patent number: 6984644
    Abstract: The invention provides pharmaceutically useful thieno[2,3-d]pyrimidinediones, processes for their production, pharmaceutical compositions containing them and methods of treatment involving their use.
    Type: Grant
    Filed: October 7, 2002
    Date of Patent: January 10, 2006
    Assignee: AstraZeneca AB
    Inventors: David Cheshire, Andrew Cooke, Martin Cooper, David Donald, Mark Furber, Matthew Perry, Philip Thorne
  • Adamantane derivatives
    Patent number: 6881754
    Abstract: The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CH2 or CH2CH2, E represents C(O)NH or NHC(O) and R3 represents a group of formula (I).
    Type: Grant
    Filed: December 12, 2000
    Date of Patent: April 19, 2005
    Assignee: AstraZeneca AB
    Inventors: Lilian Alcaraz, Moya Caffrey, Mark Furber, Timothy Luker, Michael Mortimore, Austen Pimm, Philip Thorne, Paul Willis
  • Adamantane derivatives
    Publication number: 20050049303
    Abstract: The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CH2 or CH2CH2, E represents C(O)NH or NHC(O) and R3 represents a group of formula (I).
    Type: Application
    Filed: March 31, 2004
    Publication date: March 3, 2005
    Inventors: Lilian Alcaraz, Mark Furber, Michael Mortimore, Austen Pimm, Philip Thorne, Paul Willis
  • Substituted fused pyridazinone compounds; composition and use thereof
    Patent number: 6770646
    Abstract: The invention provides certain pyrrolo-, thieno-, furano-and pyrazolo-[3,4-d]-pyridazinones, processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and methods of treatment involving their use.
    Type: Grant
    Filed: December 10, 2001
    Date of Patent: August 3, 2004
    Assignee: AstraZeneca AB
    Inventors: John Bantick, Martin Cooper, Philip Thorne, Matthew Perry
  • Adamantane derivatives
    Patent number: 6720452
    Abstract: The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.
    Type: Grant
    Filed: June 10, 2002
    Date of Patent: April 13, 2004
    Assignee: AstraZeneca AB
    Inventors: Lilian Alcaraz, Mark Furber, Timothy Luker, Michael Mortimore, Philip Thorne
  • Thieno[2,3-d]pyrimidinediones, their preparation and use in therapy
    Publication number: 20030191142
    Abstract: The invention provides pharmaceutically useful thieno[2,3-d]pyrimidinediones, processes for their production, pharmaceutical compositions containing them and methods of treatment involving their use.
    Type: Application
    Filed: October 7, 2002
    Publication date: October 9, 2003
    Applicant: AstraZeneca AB
    Inventors: David Cheshire, Andrew Cooke, Martin Cooper, David Donald, Mark Furber, Matthew Perry, Philip Thorne
  • Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions
    Patent number: 6555541
    Abstract: The invention provides substituted phenyl compounds of general formula wherein R1, T, U and Ar are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.
    Type: Grant
    Filed: July 10, 2000
    Date of Patent: April 29, 2003
    Assignee: Astrazeneca UK Limited
    Inventors: Mark Furber, Timothy J Luker, Michael P Mortimore, Philip Thorne, Premji Meghani
  • Adamantane derivatives
    Publication number: 20030013704
    Abstract: 1
    Type: Application
    Filed: June 12, 2002
    Publication date: January 16, 2003
    Inventors: Lilian Alcaraz, Moya Caffrey, Mark Furber, Timothy Luker, Michael Mortimore, Austen Pimm, Philip Thorne, Paul Willis
  • Adamantane derivatives
    Publication number: 20020193414
    Abstract: The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.
    Type: Application
    Filed: June 10, 2002
    Publication date: December 19, 2002
    Inventors: Lillian Alcaraz, Mark Furber, Timothy Luker, Michael Mortimore, Philip Thorne
  • Novel compounds
    Publication number: 20020183337
    Abstract: The invention provides pharmaceutically useful thieno[2,3-d]pyrimidinediones, processes for their production, pharmaceutical compositions containing them and methods of treatment involving their use.
    Type: Application
    Filed: October 17, 2001
    Publication date: December 5, 2002
    Applicant: AstraZeneca AB.
    Inventors: David Cheshire, Andrew Cooke, Martin Cooper, David Donald, Mark Furber, Matthew Perry, Philip Thorne
  • Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy
    Patent number: 6469014
    Abstract: The invention provides pharmaceutically useful thieno[2,3-d]pyrimidinediones, processes for their production, pharmaceutical compositions containing them and methods of treatment involving their use.
    Type: Grant
    Filed: October 17, 2001
    Date of Patent: October 22, 2002
    Assignee: AstraZeneca AB
    Inventors: David Cheshire, Andrew Cooke, Martin Cooper, David Donald, Mark Furber, Matthew Perry, Philip Thorne
  • Novel compounds
    Publication number: 20020099055
    Abstract: The invention provides certain pyrrolo-, thieno-, furano-and pyrazolo-[3,4-d]-pyridazinones, processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and methods of treatment involving their use.
    Type: Application
    Filed: December 10, 2001
    Publication date: July 25, 2002
    Applicant: AstraZeneca AB.
    Inventors: John Bantick, Martin Cooper, Philip Thorne, Matthew Perry
  • Compounds
    Patent number: 6342601
    Abstract: The invention provides certain pyrrolo-, thieno-, furano- and pyrazolo-[3,4-d]pyridazinones, processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and methods of treatment involving their use.
    Type: Grant
    Filed: January 12, 1999
    Date of Patent: January 29, 2002
    Assignee: AstraZeneca AB
    Inventors: John Bantick, Martin Cooper, Philip Thorne, Matthew Perry
  • Thieno[2,3-d]pyrimidine diones and their use in the treatment of reversible obstructive airways diseases
    Patent number: 6342502
    Abstract: The invention provides pharmaceutically useful thieno[2,3-d]pyrimidinediones, processes for their production, pharmaceutical compositions containing them and methods of treatment involving their use.
    Type: Grant
    Filed: October 23, 2000
    Date of Patent: January 29, 2002
    Assignee: AstraZeneca AB
    Inventors: David Cheshire, Andrew Cooke, Martin Cooper, David Donald, Mark Furber, Matthew Perry, Philip Thorne
  • Thieno[2,3-d]pyrimidine-2,4-diones
    Patent number: 6300334
    Abstract: Compounds of formula (I): wherein R1, R2, and R3 are defined in the specification. The compounds are useful for treating or reducing the risk of reversible obstructive airways disease.
    Type: Grant
    Filed: October 13, 1999
    Date of Patent: October 9, 2001
    Assignee: AstraZeneca AB
    Inventors: John Bantick, Martin Cooper, Matthew Perry, Philip Thorne